RAB10: an Alzheimer’s disease resilience locus and potential drug target
Justina P Tavana,1,* Matthew Rosene,2,* Nick O Jensen,2 Perry G Ridge,1 John SK Kauwe,1,3 Celeste M Karch2,4 1Department of Biology, Brigham Young University, Provo, UT 84602, USA; 2Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA; 3Department of Neuroscience, Brigham...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/eb7048d406034231a0061c376e346c0a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:eb7048d406034231a0061c376e346c0a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:eb7048d406034231a0061c376e346c0a2021-12-02T01:03:26ZRAB10: an Alzheimer’s disease resilience locus and potential drug target1178-1998https://doaj.org/article/eb7048d406034231a0061c376e346c0a2018-12-01T00:00:00Zhttps://www.dovepress.com/rab10-an-alzheimers-disease-resilience-locus-and-potential-drug-target-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Justina P Tavana,1,* Matthew Rosene,2,* Nick O Jensen,2 Perry G Ridge,1 John SK Kauwe,1,3 Celeste M Karch2,4 1Department of Biology, Brigham Young University, Provo, UT 84602, USA; 2Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA; 3Department of Neuroscience, Brigham Young University, Provo, UT 84602, USA; 4Hope Center for Neurological Disorders, Washington University in St Louis, St Louis, MO, USA *These authors contributed equally to this work Abstract: Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10. Keywords: Alzheimer’s disease, RAB10, retromer, APP, resilience, GTPaseTavana JPRosene MJensen NORidge PGKauwe JSKKarch CMDove Medical PressarticleAlzheimer diseaseRAB10RetromerAPPresilienceGTPaseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 14, Pp 73-79 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Alzheimer disease RAB10 Retromer APP resilience GTPase Geriatrics RC952-954.6 |
| spellingShingle |
Alzheimer disease RAB10 Retromer APP resilience GTPase Geriatrics RC952-954.6 Tavana JP Rosene M Jensen NO Ridge PG Kauwe JSK Karch CM RAB10: an Alzheimer’s disease resilience locus and potential drug target |
| description |
Justina P Tavana,1,* Matthew Rosene,2,* Nick O Jensen,2 Perry G Ridge,1 John SK Kauwe,1,3 Celeste M Karch2,4 1Department of Biology, Brigham Young University, Provo, UT 84602, USA; 2Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA; 3Department of Neuroscience, Brigham Young University, Provo, UT 84602, USA; 4Hope Center for Neurological Disorders, Washington University in St Louis, St Louis, MO, USA *These authors contributed equally to this work Abstract: Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3'-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10. Keywords: Alzheimer’s disease, RAB10, retromer, APP, resilience, GTPase |
| format |
article |
| author |
Tavana JP Rosene M Jensen NO Ridge PG Kauwe JSK Karch CM |
| author_facet |
Tavana JP Rosene M Jensen NO Ridge PG Kauwe JSK Karch CM |
| author_sort |
Tavana JP |
| title |
RAB10: an Alzheimer’s disease resilience locus and potential drug target |
| title_short |
RAB10: an Alzheimer’s disease resilience locus and potential drug target |
| title_full |
RAB10: an Alzheimer’s disease resilience locus and potential drug target |
| title_fullStr |
RAB10: an Alzheimer’s disease resilience locus and potential drug target |
| title_full_unstemmed |
RAB10: an Alzheimer’s disease resilience locus and potential drug target |
| title_sort |
rab10: an alzheimer’s disease resilience locus and potential drug target |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/eb7048d406034231a0061c376e346c0a |
| work_keys_str_mv |
AT tavanajp rab10analzheimerrsquosdiseaseresiliencelocusandpotentialdrugtarget AT rosenem rab10analzheimerrsquosdiseaseresiliencelocusandpotentialdrugtarget AT jensenno rab10analzheimerrsquosdiseaseresiliencelocusandpotentialdrugtarget AT ridgepg rab10analzheimerrsquosdiseaseresiliencelocusandpotentialdrugtarget AT kauwejsk rab10analzheimerrsquosdiseaseresiliencelocusandpotentialdrugtarget AT karchcm rab10analzheimerrsquosdiseaseresiliencelocusandpotentialdrugtarget |
| _version_ |
1718403352048435200 |